| (Philadelphia, PA) - Researchers at the University
of Pennsylvania School of Medicine recently discovered
a novel mechanism that works over an extensive genomic distance
and controls the expression of human growth hormone (hGH)
in the pituitary gland. This mechanism involves a newly discovered
set of “non-coding RNAs” expressed in the vicinity of
the hGH gene.
By examining the relationship between these non-coding RNAs and
the hGH gene, researchers hope to understand how
these remote regions impact hGH gene expression
and dysfunction. Such insight may aid researchers in the development
of therapeutics for growth hormone defects and lead to a greater
understanding of the causes of other genetic disorders.
The human genome is comprised of both non-coding DNA and coding
regions, or genes. While researchers once believed that only genes
were transcribed into messenger RNA (mRNA), investigators have recently
discovered that non-coding DNA is copied into mRNA as well. Unlike
coding mRNAs, which are translated into functional proteins and
peptides, the function of most non-coding RNAs is unclear. Although
non-coding RNAs fail to produce functional proteins, researchers
believe that in some cases these RNAs may control gene expression.
Using a genetically modified mouse model, Nancy E. Cooke,
MD, Stephen A. Liebhaber, MD, Professors
of Genetics and Medicine, and colleagues, demonstrated a critical
role of two non-coding regions on the activation of the hGH
gene. They described their recent findings in the August issue of
Molecular Cell.
Synthesized by the pituitary gland, human growth hormone activates
growth and cell reproduction. In addition to serving as a major
contributor to height growth during childhood, hGH plays
a role in strengthening bones and increasing muscle mass throughout
life. While mutations to the hGH gene often lead
to abnormal growth in children and adults, these mutations have
provided researchers with key clues regarding the genomic areas
that appear to control expression of the hGH gene.
Previous work in the laboratories of Cooke and Liebhaber found that
the hGH gene is controlled by a non-coding DNA
region, or locus control region. Remarkably, this region is located
more than 14,000 base pairs away from the hGH
gene. At the genomic level, a 14,000 base-pair separation is equal
to the size of 10 growth hormone genes lined end to end. “The
effects of the locus control region on human growth hormone expression
is as if you turn a key in the lock of a house at one end of your
street, and find that this action opens the lock and door of a house
a block away,” notes Liebhaber.
By carefully analyzing the 14,000 base pairs separating the hGH
gene and its locus control region, co-authors Yugong Ho,
PhD, an Instructor of Genetics at Penn and a Cooke/Liebhaber
lab member, and Felice Elefant, PhD, Assistant Professor at Drexel
University and former member of the Cooke/Liebhaber lab, found that
the locus control region was copied into RNA, and discovered a gene
called CD79b within this region. Remarkably this
CD79b gene was also copied into RNA in the pituitary.
While the CD79b gene normally codes for a protein
in blood lymphocytes, researchers discovered that CD79b
appears to play a very different role in the pituitary gland. Here,
CD79b was actively transcribed into mRNA, but this mRNA
failed to translate into a functional protein. Instead, the non-coding
RNA was suspected to play a role in hGH gene regulation.
In order to determine whether the CD79b RNA in the pituitary
gland served a function, Ho inserted a segment of human DNA that
included hGH, the hGH locus control region, and
CD79b into a group of mice. As a result, the transgenic
mice expressed high levels of human growth hormone in the pituitary
as well as mouse growth hormone. To test whether the transcription
of the locus control region and CD79b played a significant
role in hGH expression in transgenic mice, Ho then inserted
a special piece of DNA into the locus control region. This DNA insertion
specifically blocked the copying of the CD79b gene into
RNA in the pituitary. This blockade led to the five-fold repression
of hGH gene expression. These findings confirm that the
CD79b non-coding DNA actively contributes to hGH
expression. The relationship between CD79b, the hGH
locus control region, and the hGH gene may aid researchers
in the development of treatments for patients suffering from hGH
deficiency.
“Our data predict that a subset of children with short stature
and low growth hormone may be suffering from a mutation in the hGH
locus control region, which blocks full levels of hGH gene
activity,” explains Ho. “We are now actively screening
the appropriate clinical populations for such genetic defects.”
In the future, Cooke, Liebhaber, and Ho will continue to search
for how transcription contributes to long-range activation of hGH
gene expression through the development of new transgenic mouse
models and the biochemical analysis of the hGH locus.
“By understanding how non-coding DNA functions at the human
growth hormone locus, researchers may be able to identify similar
situations at other genetic loci,” says Liebhaber.
“With every step forward in understanding how genes are expressed,
we increase our awareness of how naturally occurring and acquired
mutations interfere with this process,” adds Cooke. “Our
research sets the groundwork for advances in diagnosis and eventual
treatment of genetic diseases.”
These studies were funded by the National Institutes of Health.
###
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice. |